Stereotaxis, Inc. (STXS) Stock Price & Analysis
Stereotaxis, Inc. (STXS) closed at USD 1.05 on Thursday, October 15, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.05; the Oct 15, 2026 session ranged USD 1.02–1.06 on volume of 640,202 shares. Market capitalization is $105.21M, with a 52-week range of USD 1.02–3.15 (ASE). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/STXS.md
Key facts (STXS)
- Last four reported quarters (through Jun 30, 2026): revenue $30.1M, net income -$22.3M (-74.2% margin), free cash flow -$15.5M (SEC filings).
- Analysts: Buy (mean 1.67 on a 1–5 scale) (3 analysts), mean target USD 3 (range 3–3).
- Total return with dividends: 1Y -65.3% vs S&P 500 +18.1%; 5Y -82.3% vs S&P 500 +85.1%.
- Next earnings: 2026-11-16, EPS estimate USD -0.06, revenue estimate $9.6M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (STXS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $35.0M | $28.1M | $26.8M | $26.9M | $32.4M | $30.1M |
| Gross profit | $23.2M | $18.5M | $14.9M | $14.6M | $17.1M | — |
| Operating income | -$12.9M | -$18.8M | -$21.8M | -$24.7M | -$22.1M | -$22.8M |
| Net income | -$10.7M | -$18.3M | -$20.7M | -$24.0M | -$21.6M | -$22.3M |
| EPS (diluted) | -$0.16 | -$0.26 | -$0.27 | -$0.30 | -$0.25 | — |
| Free cash flow | -$4.3M | -$10.8M | -$9.5M | -$8.5M | -$13.8M | -$15.5M |
| Gross margin | 66.3% | 65.6% | 55.5% | 54.2% | 52.7% | — |
| Operating margin | -36.8% | -66.7% | -81.6% | -91.9% | -68.3% | -75.7% |
| Net margin | -30.6% | -65.0% | -77.4% | -89.3% | -66.8% | -74.2% |
| Revenue growth | +31.5% | -19.6% | -4.9% | +0.5% | +20.3% | — |
| Cash + short-term investments | $38.7M | $28.4M | — | $12.2M | $13.4M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (STXS)
P/S 3.5x · P/B 8.6x · FCF yield -14.73% · Earnings yield -21.22% · Dividend yield (paid, TTM) 0.00%
Analysts (STXS)
Consensus Buy (mean 1.67 on a 1–5 scale), 3 analysts; mean target USD 3 (low 3, high 3).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-27 | Citizens | Target lowered | Market Outperform | $4 → $3 |
| 2026-08-12 | TD Cowen | Target lowered | Buy | $5 → $3 |
Total return (dividends reinvested) (STXS)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -65.3% | -82.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -65.5% | -29.2% |
| Volatility (annualized) | 51.3% | 59.0% |
| Max drawdown | -66.1% (Oct 2025→Oct 2026) | -83.9% (Nov 2021→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 1.05 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.05 |
| Open | USD 1.04 |
| Day Range | USD 1.02 – 1.06 |
| 52-Week Range | USD 1.02 – 3.15 |
| Volume | 640,202 shares |
| Market Cap | $105.21M |
| Exchange | ASE |
Technical Analysis (STXS)
Nexqual's technical model rates STXS "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 22.1 (oversold) |
| vs SMA50 | Below (USD 1.31) |
| MACD | -0.08 (negative) |
Analyst Ratings (STXS)
Wall Street analysts rate STXS "Buy" based on 3 analysts, with a mean price target of USD 3 (range USD 3–3), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 3 |
| High Target | USD 3 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (STXS)
| Next Earnings Date | 2026-11-16 |
|---|---|
| EPS Estimate | USD -0.06 |
| Revenue Estimate | $9.60M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.05 vs est -0.05 ▼ miss |
| 2025-12-31 | USD -0.06 vs est -0.07 ▲ beat |
| 2025-09-30 | USD -0.07 vs est -0.06 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (STXS)
| Total Revenue | $30.07M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -12.80% |
| Gross Margin | +55.57% |
| Operating Margin | -59.56% |
| Profit Margin | -74.24% |
| ROE | -184.27% |
| Debt / Equity | 0.3 |
| Current Ratio | 1.42 |
| Total Cash | $10.49M |
| Total Debt | $5.17M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$13.78M (-42.6% of revenue) |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (STXS)
Nexqual rates Stereotaxis, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $10M cash vs $5M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$14M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -184%, ROA -25.4% |
Ownership (STXS)
| Insider Ownership | +15.20% |
|---|---|
| Institutional Ownership | +49.72% |
| Shares Outstanding | 100.20M |
| Float | 65.54M |
| Short % of Float | +6.70% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (STXS)
Stereotaxis, Inc. is led by David Leo Fischel C.A.I.A., C.F.A., C.P.A. (age 38), CEO & Chairman, per Nexqual as of October 16, 2026 at 05:21 UTC.
| CEO & Chairman | David Leo Fischel C.A.I.A., C.F.A., C.P.A. (age 38) |
|---|---|
| Chief Financial Officer | Kimberly R. Peery (age 56) |
| Vice President of Operations | Keith Galloway |
Major Backers & Investors (STXS)
Notable institutional backers of Stereotaxis, Inc. include DAFNA Capital Management, LLC, Lagoda Investment Management, L.P., Arbiter Partners Capital Management LLC, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DAFNA Capital Management, LLC | 20.73% |
| Lagoda Investment Management, L.P. | 6.25% |
| Arbiter Partners Capital Management LLC | 4.37% |
| Essex Investment Management Co LLC | 2.31% |
| Archon Capital Management LLC | 1.86% |
| Fidelity | 1.79% |
| Warberg Asset Management LLC | 1.68% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.42% |
| Vanguard Group | 9.59% |
| Geode Capital | 2.87% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
From Stereotaxis, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
- The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems.
- It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems.
- In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KMTS | Kestra Medical Technologies, Lt | USD 28.68 | ▲ 6.34% |
| XRAY | DENTSPLY SIRONA Inc. | USD 8.83 | ▲ 3.76% |
| LMAT | LeMaitre Vascular, Inc. | USD 83.16 | ▲ 1.97% |
| ATRC | AtriCure, Inc. | USD 57.78 | ▲ 1.6% |
| WRBY | Warby Parker Inc. | USD 24.59 | ▼ 7.28% |
| PLSE | Pulse Biosciences, Inc | USD 45.59 | ▼ 6.08% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt